Deafness neurosensory – European Clinical Trials Information Network

Study on the Effects of Intracochlear Triamcinolone Acetonide for Patients with Persistent Sudden Sensorineural Hearing Loss After Unsuccessful Conservative Treatment

Wed, 29 Apr 2026 15:02:10 +0000

This clinical trial is focused on studying the effects of a treatment for sudden sensorineural hearing loss, a condition where a person experiences a rapid loss of hearing, usually in one ear. The treatment being tested is an injection of a medication called triamcinolone acetonide, which is delivered directly into the cochlea, the part of the inner ear responsible for hearing. This medication is known by the brand name Volon® A 40 mg-Kristallsuspension-Spritzampulle.

The purpose of the study is to evaluate how well this treatment improves hearing in patients who have not responded to other treatments, such as oral or ear injections of steroids. Participants in the study will receive either the triamcinolone acetonide injection or a placebo. The study will observe changes in hearing ability over a period of time, using tests that measure how well participants can hear different tones and understand speech.

Throughout the study, participants will undergo various hearing tests, including the pure tone audiometry, which measures the ability to hear sounds at different pitches, and speech tests to assess how well they can understand spoken words. The study aims to provide insights into the effectiveness of this treatment for those with persistent hearing loss after other therapies have failed.

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Wed, 29 Apr 2026 14:27:30 +0000

This clinical trial is focused on studying a condition known as Idiopathic Sudden Sensorineural Hearing Loss, which is a rapid loss of hearing that occurs without a known cause. The study is comparing two treatments: a single injection of a medication called AC102 into the middle ear and oral tablets of a steroid called Prednisolone. The purpose of the study is to evaluate how effective, safe, and tolerable these treatments are for patients experiencing sudden hearing loss.

Participants in the study will receive either the AC102 injection or the oral Prednisolone tablets. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will monitor changes in hearing ability over a period of time, specifically looking at improvements in hearing thresholds, which are the softest sounds a person can hear, and speech recognition, which is the ability to understand spoken words.

The study will take place over several weeks, with participants attending regular visits to assess their hearing progress. The main goal is to see if there is an improvement in hearing from the start of the study to the end, which is approximately 28 days after treatment begins. Additional assessments will be conducted up to 84 days to further evaluate the long-term effects of the treatments. This research aims to provide valuable insights into the best treatment options for those affected by sudden hearing loss.

Study on ACOU085 to Prevent Hearing Loss in Testicular Cancer Patients Receiving Cisplatin

Wed, 29 Apr 2026 14:26:45 +0000

This clinical trial is focused on studying the prevention of hearing loss in patients with testicular cancer who are receiving a chemotherapy drug called cisplatin. The study will use a treatment known as ACOU085, which is a small molecule designed to help protect hearing. ACOU085 is administered as a thermo-reversible hydrogel through a transtympanic injection, which means it is injected directly into the ear. The trial will also include a placebo group for comparison.

The purpose of the study is to determine the safety, tolerability, and effectiveness of ACOU085 in preventing hearing loss caused by cisplatin, which is known to potentially damage hearing. Participants will receive repeated doses of ACOU085 over a period of time. The study will involve regular assessments of hearing function to monitor any changes and to compare the effects between the ear treated with ACOU085 and the ear that received the placebo.

Throughout the study, participants will undergo various hearing tests to evaluate their hearing ability, including tests for pure tone and speech recognition in both quiet and noisy environments. The study will also monitor for any side effects or adverse reactions, particularly at the injection site. The trial aims to provide valuable information on whether ACOU085 can effectively prevent hearing loss in patients undergoing treatment with cisplatin for testicular cancer.

Study of Hyperbaric Oxygen Therapy Combined with Standard Treatment for Patients with Sudden Hearing Loss

Wed, 29 Apr 2026 14:23:09 +0000

This study focuses on idiopathic sudden sensorineural hearing loss, a condition where hearing suddenly deteriorates without a known cause. The study aims to determine if adding hyperbaric oxygen treatment to standard care can improve hearing outcomes better than standard care alone. Hyperbaric oxygen involves breathing pure oxygen in a pressurized chamber.

During the study, participants will receive either standard care treatment alone or standard care combined with hyperbaric oxygen therapy. The treatment involves breathing a mixture of nitrous oxide and oxygen through inhalation. The maximum treatment period is 16 days, with each session lasting up to 95 minutes. The total treatment time may reach up to 1520 minutes across all sessions.

Hearing ability will be measured using various tests throughout the study period, with a particular focus on hearing levels after three months of treatment. The study will track changes in hearing ability, word recognition, and how the treatment affects participants’ daily communication abilities and overall quality of life.